The clinicopathological role of Bcl-2 in breast cancer was systematically investigated in 634 cases without any adjuvant therapy and 447 cases with tamoxifen monotherapy using full sections from routinely processed archival materials as used in the clinical setting. This evidence concerns the gene BCL2 and breast carcinoma.